A. S. Lok, B. J. Mcmahon, G. Yamanaka, T. Wilson, S. Innaimo et al., Chronic hepatitis B Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus, Antimicrob. Agents Chemother, vol.43, pp.190-193, 1999.

M. Zhu, M. Bifano, X. Xu, Y. Wang, F. Lacreta et al., Lack of an Effect of Human Immunodeficiency Virus Coinfection on the Pharmacokinetics of Entecavir in Hepatitis B Virus-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.52, issue.8, pp.2836-2841, 2008.
DOI : 10.1128/AAC.01366-07

H. Vl?ková, J. Janák, T. Gottvald, F. Trejtnar, P. Solich et al., How to address the sample preparation of hydrophilic compounds: Determination of entecavir in plasma and plasma ultrafiltrate with novel extraction sorbents, LC-ESI-MS/MS method for the quantification of entecavir in human plasma and its application to bioequivalence study, pp.377-344, 2014.
DOI : 10.1016/j.jpba.2013.08.034

D. Zhang, Y. Fu, J. P. Gale, A. F. Aubry, and M. E. Arnold, A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LC???MS/MS, Journal of Pharmaceutical and Biomedical Analysis, vol.49, issue.4, pp.49-1027, 2009.
DOI : 10.1016/j.jpba.2009.02.003

L. Nováková, T. Gottvald, H. Vl?ková, F. Trejtnar, J. Mandíková et al., Highly sensitive fast determination of entecavir in rat urine by means of hydrophilic interaction chromatography???ultra-high-performance liquid chromatography???tandem mass spectrometry, Journal of Chromatography A, vol.1259
DOI : 10.1016/j.chroma.2012.03.078

D. E. Morisky, L. W. Green, and D. M. Levine, Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence, Medical Care, vol.24, issue.1, pp.67-74, 1986.
DOI : 10.1097/00005650-198601000-00007

E. H. Denny-yifei and . Liu, Determination of Entecavir in Human Plasma using LC, MS/MS, Sci. Discip. Sci. Ingenuity. Web Www.tandemlabs.com, 2014.

R. Bibliographiques, European Association for the Study of the Liver, EASL Clinical Practice Guidelines: Management of chronic hepatitis B, J. Hepatol, vol.50, issue.1, pp.227-242, 2009.

A. Chaturvedula, M. J. Fossler, and C. W. Hendrix, Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies, The Journal of Clinical Pharmacology, vol.35, issue.4, pp.54-150, 2014.
DOI : 10.1002/jcph.221

C. Lu, Y. Jia, L. Chen, Y. Ding, J. Yang et al., Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers, Journal of Clinical Pharmacy and Therapeutics, vol.37, issue.2, pp.136-140, 2013.
DOI : 10.1111/jcpt.12023

A. Marengo, D. Bitetto, A. D. Avolio, A. Ciancio, C. Fabris et al., Clinical and virologic response to entecavir in HBV related chronic hepatitis or cirrhosis: data from the clinical practice in a single centre cohort, Antiviral Therapy, vol.18, issue.1, pp.87-94, 2013.
DOI : 10.3851/IMP2284

M. Zhu, M. Bifano, X. Xu, Y. Wang, F. Lacreta et al., Lack of an Effect of Human Immunodeficiency Virus Coinfection on the Pharmacokinetics of Entecavir in Hepatitis B Virus-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.52, issue.8, pp.2836-2841, 2008.
DOI : 10.1128/AAC.01366-07

A. Alpert, Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds, Journal of Chromatography A, vol.499, pp.499-177, 1990.
DOI : 10.1016/S0021-9673(00)96972-3

P. Marquet, Théorie et instrumentation des techniques de LC-MS et LC-MS / MS applicables à la toxicologie LC-MS and LC-MS / MS theory and instruments applicable to toxicology, Ann. Toxicol. Anal. XVII, p.1, 2005.

A. Montchaud, Fréquence et signification des blips au cours du traitement de l'hépatite B par analogues de deuxième génération, Thèse de doctorat en médecine, 2014.